BSX Stock Recent News
BSX LATEST HEADLINES
Boston Scientific (BSX) registers a strong year-over-year improvement in sales, indicating solid market share gains in legacy businesses across all geographic regions.
Boston Scientific (BSX) posted an increase in second-quarter earnings and sales on the back of growing demand for its heart devices.
Boston Scientific Corporation (NYSE:BSX ) Q2 2024 Earnings Conference Call July 24, 2024 8:00 AM ET Company Participants Jon Monson - SVP, IR Michael F. Mahoney - Chairman and CEO Daniel J.
While the top- and bottom-line numbers for Boston Scientific (BSX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Boston Scientific (BSX) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.58 per share. This compares to earnings of $0.53 per share a year ago.
Boston Scientific raised its full-year profit forecast on Wednesday on the back of strong demand for its heart devices, sending the medical device maker's shares up 2% in premarket trading.
Boston Scientific (NYSE: BSX) is scheduled to report its Q2 2024 results on Wednesday, July 24. We expect the company to report revenues and earnings in line with the consensus estimates.
Investors looking for stocks in the Medical - Products sector might want to consider either Haemonetics (HAE) or Boston Scientific (BSX). But which of these two stocks offers value investors a better bang for their buck right now?
Investors interested in Medical - Products stocks are likely familiar with Haemonetics (HAE) and Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now?
In EMEA, Boston Scientific (BSX) is successfully expanding its base, banking on its diverse portfolio, new launches and commercial execution with healthy underlying market demand.